Are SMS Pharma. latest results good or bad?

SMS Pharmaceuticals has reported its financial results for the quarter ending March 2025, indicating a notable performance across several key metrics. The company achieved its highest quarterly net sales in the last five quarters, reaching Rs 248.20 crore, which reflects a substantial increase compared to the average net sales from the previous four quarters. This growth is complemented by a peak in operating profit before depreciation, interest, and tax (PBDIT) at Rs 40.81 crore, suggesting an enhancement in operational efficiency.
The profit before tax (PBT) also demonstrated a significant rise, reaching Rs 27.10 crore, which is higher than the average from the prior quarters. Furthermore, the profit after tax (PAT) was reported at Rs 20.32 crore, indicating an upward trend compared to the previous average. The earnings per share (EPS) reached Rs 2.29, highlighting improved profitability for the company.

In terms of quarterly performance, the net sales showed a growth of 43.18% compared to the previous quarter, while the consolidated net profit experienced an increase of 11.40%. However, the operating profit margin saw a slight decline, indicating a mixed trend in operational profitability.

Overall, SMS Pharmaceuticals has demonstrated a positive financial performance for the quarter, and the company saw an adjustment in its evaluation following these results.